Biblio
CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation. Methods Mol Biol. 2020;2115:471-483.
. CRISPR/Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia. Mol Ther. 2024.
Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring mutations. Haematologica. 2023.